Ledger.

Company

CMAX

Adelaide, SA

Coverage

Stories naming CMAX. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series A $29m

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Brandon Capital portfolio Tue 3 Aug 2021 Glyscend, Inc.Brandon CapitalCentre of Research Excellence in Translating Nutritional Science to Good HealthCMAXMana CommunicationsPayPalRoyal Adelaide HospitalThiel FoundationUniversity of AdelaideBreakout LabsMedical Research Commercialisation Fund (MRCF)Santé VenturesAshish NimgaonkarDr Bob SohCaleb Hulme-MoirProfessor Chris RaynerCiara ByrneProfessor Michael HorowitzPeter ThielThomas Jozefiak

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’

Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.

Brandon Capital portfolio Tue 3 Aug 2021 GlyscendCMAXMedical Research Commercialisation Fund (MRCF)PayPalRoyal Adelaide HospitalUniversity of AdelaideBrandon CapitalBreakout LabsSanté VenturesAshish NimgaonkarProfessor Chris RaynerPeter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.

Brandon BioCatalyst portfolio Tue 3 Aug 2021 GlyscendBrandon CapitalCMAXPayPalRoyal Adelaide HospitalUniversity of AdelaideBreakout LabsMedical Research Commercialisation Fund (MRCF)Santé VenturesAshish NimgaonkarandProfessor Chris RaynerPeter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Something wrong? Tell us